The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Assessment of clinical trials in oncology: An evaluation of 40,696 trials on
B. R. Hirsch
No relevant relationships to disclose
R. M. Califf
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline;; Kowa ; Medtronic; Merck; Novartis; Sanofi ; Xoma
Stock Ownership - Nitrox
Research Funding - Amylin; Johnson & Johnson; Lilly; Merck; Novartis; Schering-Plough
A. Tasneem
No relevant relationships to disclose
K. Chiswell
No relevant relationships to disclose
J. Bolte
No relevant relationships to disclose
K. A. Schulman
Consultant or Advisory Role - Advanced Health Media; Blue Cross Blue Shield ; Forest Laboratories; GlaxoSmithKline; Johnson & Johnson; McKinsey and Company; Medtronic; Merck; Novartis; Novo Nordisk; Orexigen; Quintiles
Stock Ownership - Alnylam; Cancer Consultants; Faculty Connection
Research Funding - Actelion; Allergan; Alnylam; Amgen; Amylin; Astellas Pharma; Bristol-Myers Squibb; Inspire Pharmaceuticals; Johnson & Johnson; Kureha; Medtronic; Merck; Merck; Nabi Biopharmaceuticals; Novartis; OSI Pharmaceuticals; Sanofi ; Scios; Tengion; Theravance; Vertex
A. P. Abernethy
Consultant or Advisory Role - Amgen; Helsinn Therapeutics; Proventys
Research Funding - Alexion Pharmaceuticals; Amgen; BioVex; Bristol-Myers Squibb; Helsinn Therapeutics; KangLaiTe; Lilly; Pfizer